| scholarly article | Q13442814 |
| P50 | author | Michael S Hofman | Q53198887 |
| Gonçalo Ferreira | Q89289010 | ||
| P2093 | author name string | Rodney J Hicks | |
| Amir Iravani | |||
| P2860 | cites work | How We Read Oncologic FDG PET/CT | Q28066962 |
| Prostate-specific membrane antigen expression as a predictor of prostate cancer progression | Q28289877 | ||
| 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy | Q33429398 | ||
| A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen | Q33763004 | ||
| From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors | Q34978457 | ||
| Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. | Q35604902 | ||
| Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer | Q35645376 | ||
| Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer | Q35938051 | ||
| Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis | Q36065223 | ||
| Noise considerations for PET quantification using maximum and peak standardized uptake value | Q36158583 | ||
| Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer | Q37091554 | ||
| Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. | Q37240835 | ||
| Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors | Q37649127 | ||
| F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients | Q37662669 | ||
| Liver SULmean at FDG PET/CT: interreader agreement and impact of placement of volume of interest. | Q38072413 | ||
| Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy | Q38597244 | ||
| PSMA Ligands for PET-Imaging of Prostate Cancer. | Q38661165 | ||
| Prostate Specific Membrane Antigen Targeted 18F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study | Q38665724 | ||
| PSA-Stratified Performance of 18F- and 68Ga-PSMA PET in Patients with Biochemical Recurrence of Prostate Cancer. | Q38788408 | ||
| (18)F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes ; detection rate, image quality, activity kinetics and biodistribution | Q38815886 | ||
| Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer | Q38935086 | ||
| 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer | Q39449818 | ||
| Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer | Q39930921 | ||
| Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions | Q40188618 | ||
| Detection Efficacy of Hybrid 68Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. | Q40331189 | ||
| Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer | Q41319390 | ||
| PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer | Q42328242 | ||
| Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases | Q42456087 | ||
| Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18F-DCFPyL: Variability in Normal-Organ Uptake | Q45105171 | ||
| Evaluation of a new visual uptake scoring scale for 18F-fluorothymidine positron emission tomography in the diagnosis of pulmonary lesions. | Q45715221 | ||
| 68Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. | Q47147617 | ||
| Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers | Q47190664 | ||
| Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. | Q47399411 | ||
| ACCURACY OF DOSE CALIBRATORS FOR GALLIUM-68 PET IMAGING: UNEXPECTED FINDINGS IN A MULTI-CENTRE CLINICAL PRE-TRIAL ASSESSMENT. | Q50077335 | ||
| Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. | Q50103884 | ||
| Initial Experience with Volumetric 68Ga-PSMA I&T PET/CT for Assessment of Whole-Body Tumor Burden as a Quantitative Imaging Biomarker in Patients with Prostate Cancer. | Q50993432 | ||
| 68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer. | Q51646815 | ||
| Clinical PET Imaging in Prostate Cancer. | Q51809435 | ||
| 18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. | Q52654885 | ||
| PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. | Q53131398 | ||
| (68)Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. | Q54543117 | ||
| Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer | Q63966560 | ||
| Prostate-specific membrane antigen expression in normal and malignant human tissues | Q77553386 | ||
| 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer | Q88563961 | ||
| A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial pr | Q88565499 | ||
| [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study | Q88645082 | ||
| Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial 68Ga-PSMA-11 PET in Men with Hormone-Sensitive and Castrate-Resistant Prostate Cancer Commencing Androgen Blockade | Q90523242 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biodistribution | Q4914764 |
| P304 | page(s) | 23 | |
| P577 | publication date | 2019-05-15 | |
| P1433 | published in | Cancer Imaging | Q2577267 |
| P1476 | title | Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution | |
| P478 | volume | 19 |
| Q92423926 | 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging |
| Q100395448 | Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology |
| Q90598687 | Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies |
| Q92083580 | Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers-Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT |
Search more.